Egetis Therapeutics AB (publ)

OTCPK:PDPH.F Stock Report

Market Cap: US$324.3m

Egetis Therapeutics Management

Management criteria checks 3/4

Egetis Therapeutics' CEO is Nicklas Westerholm, appointed in Jun 2017, has a tenure of 8.92 years. total yearly compensation is SEK8.20M, comprised of 46.3% salary and 53.7% bonuses, including company stock and options. directly owns 0.056% of the company’s shares, worth $181.08K. The average tenure of the management team and the board of directors is 6.9 years and 3.3 years respectively.

Key information

Nicklas Westerholm

Chief executive officer

SEK 8.2m

Total compensation

CEO salary percentage46.34%
CEO tenure8.9yrs
CEO ownership0.06%
Management average tenure6.9yrs
Board average tenure3.3yrs

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has Nicklas Westerholm's remuneration changed compared to Egetis Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-SEK 374m

Dec 31 2025n/an/a

-SEK 342m

Sep 30 2025n/an/a

-SEK 333m

Jun 30 2025n/an/a

-SEK 337m

Mar 31 2025n/an/a

-SEK 331m

Dec 31 2024SEK 8mSEK 4m

-SEK 344m

Sep 30 2024n/an/a

-SEK 319m

Jun 30 2024n/an/a

-SEK 319m

Mar 31 2024n/an/a

-SEK 327m

Dec 31 2023SEK 6mSEK 3m

-SEK 327m

Sep 30 2023n/an/a

-SEK 319m

Jun 30 2023n/an/a

-SEK 286m

Mar 31 2023n/an/a

-SEK 240m

Dec 31 2022SEK 6mSEK 3m

-SEK 194m

Sep 30 2022n/an/a

-SEK 148m

Jun 30 2022n/an/a

-SEK 113m

Mar 31 2022n/an/a

-SEK 114m

Dec 31 2021SEK 5mSEK 3m

-SEK 104m

Sep 30 2021n/an/a

-SEK 147m

Jun 30 2021n/an/a

-SEK 153m

Mar 31 2021n/an/a

-SEK 155m

Dec 31 2020SEK 4mSEK 2m

-SEK 178m

Sep 30 2020n/an/a

-SEK 127m

Jun 30 2020n/an/a

-SEK 134m

Mar 31 2020n/an/a

-SEK 127m

Dec 31 2019SEK 3mSEK 2m

-SEK 61m

Compensation vs Market: Nicklas's total compensation ($USD888.73K) is below average for companies of similar size in the US market ($USD2.55M).

Compensation vs Earnings: Nicklas's compensation has increased whilst the company is unprofitable.

CEO

Nicklas Westerholm (49 yo)

8.9yrs
Tenure
SEK 8,200,000
Compensation

Mr. Nicklas Westerholm has been the Chief Executive Officer of Egetis Therapeutics AB (publ) (formerly known as PledPharma AB (publ)) since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca...

Leadership Team

NamePositionTenureCompensationOwnership
Nicklas Westerholm
Chief Executive Officer8.9yrsSEK 8.20m0.056%
$ 181.1k
Torsten Almén
Founder20.3yrsno datano data
Ingemar Lundström
Founder20.3yrsno datano data
Louis Ignarro
Founder20.3yrsno datano data
Heidi Brurok
Founder20.3yrsno datano data
Rob Towart
Founder20.3yrsno datano data
Yilmaz Mahshid
Chief Financial Officer4.9yrsno data0.042%
$ 136.9k
Katayoun Welin-Berger
Vice President of Operations3.2yrsno datano data
Karl Hard
Head of Investor Relations & Business Development4.3yrsno data0.033%
$ 106.0k
Laetitia Szaller
General Counsel and Head of Compliance & ESG2.4yrsno data0.0029%
$ 9.4k
Peter Verwaijen
Global Head of Marketing & Brand Strategy4yrsno datano data
Nils Hallen
HR Manager4.3yrsno data0.0059%
$ 19.2k
6.9yrs
Average Tenure
57yo
Average Age

Experienced Management: PDPH.F's management team is seasoned and experienced (6.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mats Blom
Chairman of the Board5.1yrsSEK 600.00k0.73%
$ 2.4m
Behshad Sheldon
Independent Director3.3yrsSEK 300.00kno data
Birgitte Volck
Directorless than a yearno datano data
Gunilla Osswald
Independent Director9.3yrsSEK 300.00k0.0087%
$ 28.1k
Elisabeth Svanberg
Independent Director9.3yrsSEK 300.00k0.0082%
$ 26.5k
Margarida Duarte
Director1yrno datano data
Jay Wu
Directorless than a yearno datano data
3.3yrs
Average Tenure
62.5yo
Average Age

Experienced Board: PDPH.F's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/09 11:25
End of Day Share Price 2026/04/28 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Egetis Therapeutics AB (publ) is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick LangstromABG Sundal Collier Sponsored
Erik HultgårdCarnegie Investment Bank AB
Ulrik TrattnerCarnegie Investment Bank AB